STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing…

Central bank currency redesign cycles and security upgrade mandates driving Crane Currency order timing and backlog
Payment technology adoption rates in retail automation, self-checkout, and cashless payment infrastructure
Aftermarket parts and service revenue growth indicating installed base health and customer retention
New product launches in authentication technology and payment acceptance solutions
moderate - Payment & Merchandising segment is tied to retail activity, vending machine placements, and commercial investment in automation, creating GDP sensitivity. However, Crane Currency provides countercyclical stability as governments maintain currency production regardless of economic conditions. Industrial production and retail sales trends affect equipment demand, but long contract cycles and government revenue sources dampen volatility compared to pure cyclical industrials.
Rising interest rates create moderate headwinds through higher financing costs for capital equipment purchases by customers and increased discount rates compressing valuation multiples. The company's 0.91 debt/equity ratio means financing costs impact profitability. However, government currency contracts are less rate-sensitive than commercial equipment sales. Higher rates may delay retail automation investments as customers face higher cost of capital for multi-year projects.
Secular decline in cash usage globally threatens long-term demand for currency production and cash-handling payment equipment, though transition timeline spans decades
Digital currency initiatives by central banks (CBDCs) could disrupt traditional banknote demand, though physical currency remains dominant in most markets
Technological disruption in payment acceptance from mobile wallets and contactless solutions reducing need for traditional validators
value - The stock trades at 1.8x sales and 11.1x EV/EBITDA with negative recent returns, attracting value investors seeking turnaround potential or undervalued industrial franchises. The specialized niche positioning and government contract stability appeal to investors seeking defensive industrial exposure with moderate growth. However, negative FCF and declining earnings growth deter growth-oriented investors. The 42.5% gross margin suggests quality business characteristics that value investors target.
Trend
-17.5% vs SMA 50 · -30.7% vs SMA 200
Momentum
Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $1.4B $1.4B–$1.4B | — | $3.21 | — | ±1% | Moderate3 |
FY2024 | $1.5B $1.5B–$1.5B | ▲ +8.5% | $4.27 | ▲ +33.0% | ±0% | Moderate4 |
FY2025 | $1.6B $1.6B–$1.6B | ▲ +9.2% | $4.05 | ▼ -5.1% | ±0% | High5 |
Dividend per payment — last 8 periods
STAAR Surgical Company delivered a robust 1Q26 beat, with revenue up 119% YoY to $93.5M and a swing…

No description available.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
CXT◀ | $38.21 | -3.97% | $2.2B | 16.9 | +1142.7% | 875.8% | 1500 |
| $404.35 | -3.20% | $2.1T | 30.5 | +3296.8% | 4510.0% | 1500 | |
| $132.58 | -6.05% | $307.9B | 20.7 | -44.8% | 1012.0% | 1500 | |
| $88.38 | -2.58% | $303.7B | 13.6 | +318.8% | 1510.7% | 1500 | |
| $148.08 | -1.13% | $282.6B | 21.0 | +597.3% | 2564.4% | 1500 | |
| $181.58 | -1.83% | $281.6B | 26.9 | +862.9% | 1745.9% | 1500 | |
| $183.40 | -0.23% | $256.1B | 16.8 | +213.3% | 1482.4% | 1500 | |
| Sector avg | — | -2.71% | — | 20.9 | +912.4% | 1957.3% | 1500 |